BB Biotech AG 13D and 13G filings for Agios Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-14 2:35 pm Sale |
2024-12-31 | 13G | Agios Pharmaceuticals, Inc. AGIO |
BB Biotech AG | 3,515,150 6.200% |
-484,850 (-12.12%) |
Filing |
| 2024-02-13 06:07 am Sale |
2023-12-31 | 13G | Agios Pharmaceuticals, Inc. AGIO |
BB Biotech AG | 4,000,000 7.200% |
-30,792 (-0.76%) |
Filing |
| 2023-02-14 4:10 pm Sale |
2022-12-31 | 13G | Agios Pharmaceuticals, Inc. AGIO |
BB Biotech AG | 4,030,792 7.300% |
-281,500 (-6.53%) |
Filing |
| 2022-02-11 4:51 pm Purchase |
2021-12-31 | 13G | Agios Pharmaceuticals, Inc. AGIO |
BB Biotech AG | 4,312,292 7.900% |
153,390 (+3.69%) |
Filing |
| 2021-02-12 4:11 pm Purchase |
2020-12-31 | 13G | Agios Pharmaceuticals, Inc. AGIO |
BB Biotech AG | 4,158,902 6.000% |
261,948 (+6.72%) |
Filing |